Combining RARP With ADT Prolongs Survival in Oligometastatic Prostate Cancer - Renal and Urology News The standard-of-care for oligometastatic prostate cancer centers on systemic therapy including ADT.

Multimodal treatment including radical prostatectomy might lead to improved survival in patients with oligometastatic prostate cancer treated with ADT.
www.renalandurologynews.com/reports/pros... #SUO2025 #prostatecancer

PSA Decline May Be Greater With Apalutamide vs Abiraterone for mCSPC - Renal and Urology News Investigators compared PSA90 response between new users of apalutamide vs abiraterone for mCSPC using a large US cohort.

Among real-world US patients with mCSPC, apalutamide users achieved PSA90 response approximately 5 months earlier than abiraterone users, with more achieving deeper PSA decline.
www.renalandurologynews.com/reports/psa-... #SUO2025 #prostatecancer

Non-Muscle Invasive Bladder Cancer That Metastasizes Has Poor Survival - Renal and Urology News Metastatic NMIBC is underexplored with prognosis unclear.

Overall survival is no better for patients diagnosed with NMIBC who progress directly to metastasis.
www.renalandurologynews.com/reports/non-... #SUO2025 #bladdercancer

Should Cytoreductive Nephrectomy be Revitalized in Metastatic RCC? - Renal and Urology News In 2024, only 5% of real-world patients with mRCC in a large database underwent cytoreductive nephrectomy.

Cytoreductive nephrectomy merits further consideration in appropriately risk-stratified, surgically fit patients with mRCC.
www.renalandurologynews.com/reports/cyto... #SUO2025 #kidneycancer

Combined PET-MRI Ups Diagnostic Accuracy of Clinically Significant Prostate Cancer - Renal and Urology News Multiparametric MRI has limited specificity in prostate cancer active surveillance.

A combined PSMA-PET/MRI scanner better detected clinically significant prostate cancer in men on active surveillance.
www.renalandurologynews.com/reports/pros... #SUO2025 #prostatecancer

Variant Histology Bladder Cancers Rising in the US - Renal and Urology News Investigators studied US trends in the diagnosis of variant histology bladder cancer using the National Cancer database.

Increases in variant histology bladder cancer in the US highlight the importance of precision in pathologic review of biopsy specimens.
www.renalandurologynews.com/reports/vari... #SUO2025 #bladdercancer

Cretostimogene Monotherapy Shows Efficacy in BCG-Naïve, CIS-Containing NMIBC - Renal and Urology News Cretostimogene grenadenorepvec and other therapies are being explored as possible alternatives to BCG in patients with high-risk non-muscle invasive bladder cancer.

Results from phase 2 CORE-008 CIS cohort with high-risk BCG-naïve NMIBC show an 83.7% complete response rate and favorable safety with cretostimogene.
www.renalandurologynews.com/reports/cret... #SUO2025 #bladdercancer

Adjuvant Atezolizumab Generates DFS, OS Benefit Regardless of Tumor Size, Nodal Status, and Prior NAC in ctDNA+ MIBC | OncLive Findings from an exploratory analysis of IMvigor011 support the use of serial ctDNA testing to guide atezolizumab use in MIBC.

Adjuvant Atezolizumab Generates DFS, OS Benefit Regardless of Tumor Size, Nodal Status, and Prior NAC in ctDNA+ MIBC #SUO2025 #blcsm www.onclive.com/view/adjuvan...

Belzutifan Maintains High, Durable Responses in VHL Disease–Associated Neoplasms At 5 Years | OncLive At 48 months, the majority of patients with VHL disease–associated tumors remained in response following treatment with belzutifan.

Belzutifan Maintains High, Durable Responses in VHL Disease–Associated Neoplasms At 5 Years #SUO2025 #SUO25 #kcsm #oncology #medtwitter
www.onclive.com/view/belzuti...

Adjuvant Pembrolizumab Delivers Long-Term Benefits in ccRCC at Increased Risk of Recurrence | OncLive Adjuvant pembrolizumab delivers sustained clinical benefits across ccRCC subgroups with no new long-term safety signals.

Adjuvant Pembrolizumab Delivers Long-Term Benefits in ccRCC at Increased Risk of Recurrence @pennmedicine.bsky.social #SUO2025 #SUO25 #kcsm #oncology www.onclive.com/view/adjuvan...

NDV-01 Elicits 92% CR Rate in High-Risk NMIBC | OncLive Novel sustained-release NDV-01 achieved a 92% CR rate in high-risk patients with NMIBC with strong safety, supporting advancement to phase 3 studies.

NDV-01 Elicits 92% CR Rate in High-Risk NMIBC @utswtxid.bsky.social #SUO2025 #SUO25 #oncology www.onclive.com/view/ndv-01-...

Relief of Venous Congestion May Improve Renal Preservation Despite Worse Baseline Function in RCC With IVC Thrombosis | OncLive Data from a comparative cohort study suggest that venous congestion is a modifiable driver of renal dysfunction in patients with RCC and IVC thrombosis.

Relief of Venous Congestion May Improve Renal Preservation Despite Worse Baseline Function in RCC With IVC Thrombosis
#SUO2025 #RCC #oncology
www.onclive.com/view/relief-...

We’re presenting new research at the upcoming #SUO2025 meeting. Our abstract presentation will reveal findings on the non-invasive detection of residual urothelial carcinoma using cell-free DNA methylation in pre-op urine and plasma samples.

Join us: http://bit.ly/4qNzLgT